Canaccord starts Palvella Therapeutics with a Buy on lead programs’ potential
As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $39 price ...
A day at the Don’t Die Summit: Inside multi-millionaire Bryan Johnson’s longevity ...
Whether you think the tech entrepreneur’s age-defying ideas are healthy or hooey, he’s attracting legions of devoted fans ...